Subscribe
Logo smallSearch

KDd regimen is the most urgent reimbursement need for second-line plasmocytic myeloma treatment

MedExpress Team

Piotr Wójcik

Published Dec. 21, 2023 15:00

KDd regimen is the most urgent reimbursement need for second-line plasmocytic myeloma treatment - Header image
Fot. MedExpress TV
As of January, a decision will take effect that will significantly improve first-line treatment options for plasmocytic myeloma. However, this raises reimbursement challenges for patients with relapsed disease. The most pressing need is to include the KDd regimen in second-line reimbursement.

From the beginning of the year, daratumumab, which was previously reimbursed in the dara-VTD regimen for patients eligible for transplantation now, will also be available in the daratumumab-lenalidomide-dexamethasone, or dRD, regimen for patients ineligible for transplantation. In practice, this means covering the entire population with a very modern, standards-compliant treatment.

- Such reimbursement decisions force the next ones to be made in a while, regarding reimbursement of regimens in subsequent lines of treatment. We can already see that a major challenge will be the patients who will receive lenal...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Najciekawsze oferty pracy (przewiń)